CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 42 enrolled
Drug / intervention
Hyperoncotic Albumin 20% +2 moredrug
Likely dose
Isooncotic Albumin 5% 12mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05391607
NCT05391607Phase 4Completed

Randomized Trial of Intraoperative Intravascular Effect of Hyper-oncotic 20% Albumin, Iso-oncotic 5% Albumin and Ringer Lactate During Haemorrhage in Cystectomy. A Prospective Randomized Active-controlled Single Centre Trial

Insel Gruppe AG, University Hospital Bern·interventional·Posted May 26, 2022·Updated Apr 13, 2023

In Brief

A Phase 4 clinical trial evaluating Hyperoncotic Albumin 20%, Isooncotic Albumin 5%, and 1 other intervention for Blood Loss, Surgical and Fluid Retention. Completed, enrolled 42 participants across 1 site.

Detailed Summary

Fluid intravascular replacement is usually performed with either balanced crystalloids or iso-oncotic colloids, (synthetic colloids, plasma and 5% albumin). Doubts have been raised about synthetic colloids, and albumin solutions have been used more extensively. Albumin is the main protein responsible for plasma oncotic pressure and its volume expansion effect. The mobilization of extravascular fluid by infusing a hyper-oncotic solution like 20% albumin solution has been shown, causing endogenous fluid recruitment and blood volume expansion. The primary objective of this study is to compare the effect on plasma volume expansion and fluid recruitment of 3 different types of fluids (Albumin 5% and Albumin 20% and Ringer-lactate) during the hemorrhagic phase of the cystectomy procedure. Secondary objectives are the assessment of the hemodynamic parameters during surgery and the follow-up of pro-ANP and pro-BNP peptides. Glycocalyx proteins will be followed to evaluate endothelial wall shedding and microcirculation damages.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSwitzerland
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedMay 26, 2022
Enrollment StartMay 25, 2022
Primary CompletionMar 30, 2023
Study CompletionApr 10, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.1 years ago

Interventions

Hyperoncotic Albumin 20%drug

Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.

Isooncotic Albumin 5%drug

Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.

Ringer's Lactate Crystalloid Solutions (control group)drug

Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.